



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

November 12, 2025

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 543434

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA

Dear Sir (s),

Sub: Outcome of Board Meeting held on November 12, 2025

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Wednesday, November 12, 2025, inter-alia considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025. A copy of the same is enclosed along with the Limited Review Report of the Statutory Auditors thereon in terms of SEBI (LODR) Regulations, 2015.

The Meeting of the Board of Directors of the Company commenced at 03:00 p.m. and concluded at 03.30 p.m.

Kindly take the above information on your records.

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited

Prachi Sathe
Company Secretary & Compliance Officer

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE

KAKARIA AND ASSOCIATES LLP

CHARTERED ACCOUNTANTS

UJWAL K. KAKARIA B.Com., B.L., F.C.A.

SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.

JAIPRAKASH H. SHETHIYA B.Com., F.C.A.

AMAR J. BHANUSHALI B.Com., D.T.M., F.C.A.

VINAYAK P. BAFANA B.Com., F.C.A.

YOUR REF. :

OUR REF. :

Independent Auditor's Review Report on Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,

Board of Directors of Supriya Lifescience Limited,

1. We have reviewed the accompanying statement of unaudited financial results of **Supriya Lifescience Limited** ("the Company") for the quarter ended 30th September 2025, ("the Statement"), being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing regulations")
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial

802, Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri - West,
Mumbai - 400 053 Tel: 022 26744670. Email: info@kakariaassociates.com

Website: www.kakariaassociates.com

Ced



information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 14th October, 2021 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Kakaria and Associates LLP
Chartered Accountants
FRN: 104558W/ W100601



CA. Ujwal K. Kakaria
Partner

Membership No: – 035416

Place: - Mumbai

Date: - 12th November, 2025

UDIN: - 25035416BMKTRT1310

SUPRIYA LIFESCENCE LIMITED

CIN No: L51900MH2008PLC180452

207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063. CIN: L51900MH2008PLC180452

Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com



(₹ in million)

Part I - Statement of Standalone unaudited financial results for the quarter and half year ended 30th September, 2025

Sr.No.	Particulars	Quarter ended 30-09-2025 Unaudited	Quarter ended 30-06-2025 Unaudited	Quarter ended 30-09-2024 Unaudited	Half year ended 30-09-2025 Unaudited	Half year ended 30-09-2024 Unaudited	Year ended 31-03-2025 Audited
	Income						
I	Revenue from Operations	1,998.33	1,450.74	1,661.02	3,449.07	3,267.28	6,964.85
II	Other Income	27.25	26.74	25.18	53.99	47.42	98.15
III	Total Income	2,025.58	1,477.48	1,686.20	3,503.06	3,314.70	7,063.00
2	Expenses						
a)	Cost of Materials Consumed	606.83	437.76	615.81	1,044.59	1,173.08	2,324.36
b)	Purchase of Stock in Trade	-	-	-	-	-	-
c)	Change in inventories of finished goods , work in progress & stock in trade,	(49.53)	(120.04)	(156.06)	(169.57)	(227.36)	(212.59)
d)	Employee benefit expenses	244.81	226.88	196.85	471.69	397.70	805.19
e)	Finance Cost	4.15	5.12	4.27	9.27	7.62	16.86
f)	Depreciation & amortisation expense	66.39	64.51	47.44	130.90	94.00	204.44
g)	Other expenditure	469.75	389.13	357.25	858.88	651.28	1,439.93
IV	Total Expenses	1,342.40	1,003.36	1,065.56	2,345.76	2,096.32	4,578.19
V	Profit/(loss) before Exceptional Items & Tax (III - IV)	683.18	474.12	620.64	1,157.30	1,218.38	2,484.80
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(loss) before Tax (V-VI)	683.18	474.12	620.64	1,157.30	1,218.38	2,484.80
VIII	Tax Expense						
a)	Current Tax	151.58	105.35	154.46	256.93	301.13	566.57
b)	Deferred Tax	27.33	20.87	4.69	48.20	9.33	38.66
IX	Profit/(Loss) for the period from Continuing Operations (VII-VII)	504.27	347.90	461.49	852.17	907.92	1,879.58
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	504.27	347.90	461.49	852.17	907.92	1,879.58
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	0.45	(2.87)	(2.90)	(2.42)	(3.64)	(1.67)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	(0.11)	0.72	0.73	0.61	0.92	0.42
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)	504.61	345.75	459.33	850.36	905.20	1,878.33
XVI	Earnings per equity Share (for continuing operation):						
	(1) Basic (In ₹)	6.27	4.32	5.71	10.59	11.25	23.35
	(2) Diluted (In ₹)	6.27	4.32	5.71	10.59	11.25	23.35
XVII	Earnings per equity Share (for discontinued operation):						
	(1) Basic (In ₹)	-	-	-	-	-	-
	(2) Diluted (In ₹)	-	-	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):						
	(1) Basic (In ₹)	6.27	4.32	5.71	10.59	11.25	23.35
	(2) Diluted (In ₹)	6.27	4.32	5.71	10.59	11.25	23.35



See accompanying notes to the financial statements:

Notes:-

1. The unaudited standalone financial results of the Company for the quarter ended September 30, 2025 have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as amended.
2. The above unaudited standalone financial results of the Company for the quarter ended September 30, 2025 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on November 12, 2025.
3. The Company has adopted Ind AS 116 "Leases" effective April 01, 2019, using modified retrospective method. The Company has applied the standard to all its leases with the cumulative impact recognized on the date of initial application i.e. April 01, 2019.
4. The company does not have any subsidiary/associate/joint venture company as on September 30, 2025.
5. The figures of the previous periods have been regrouped wherever necessary to confirm to the current period presentation.


Place :- Mumbai
Date :- November 12, 2025

For Supriya Lifescience Limited


Dr. Saloni Wagh
Managing director
DIN: 08491410



Particulars	September 30, 2025	March 31, 2025
ASSETS		
Non-current assets		
(i) Property, plant and equipment	4,518.95	4,468.32
(ii) Right to Use Asset	44.09	46.45
(iii) Capital Work in progress	1,724.95	1,480.15
(iv) Intangible Assets	12.14	13.89
(v) Financial Assets		
-Investments	565.48	632.41
-Loans and Advances	-	-
(vi) Other Non- Current Assets	113.42	111.54
Total Non-current assets	6,979.04	6,752.76
Current assets		
(i) Inventories	1,428.13	1,183.49
(ii) Financial Assets		
-Loans and Advances	8.20	9.27
-Trade receivables	1,551.17	1,343.62
-Cash and cash equivalents	992.63	760.57
-Bank balances other than (iii) above	39.52	30.97
-Other Financial Assets	30.28	7.11
(iii) Other current assets	1,000.61	1,035.35
Total Current Assets	5,050.54	4,370.38
TOTAL ASSETS	12,029.58	11,123.14
EQUITY AND LIABILITIES		
EQUITY		
(i) Equity share capital	160.97	160.97
(ii) Other equity	10,657.00	9,806.63
Total Equity	10,817.97	9,967.60
LIABILITIES		
Non-current liabilities		
(i) Financial Liabilities		
-Lease Liabilities	49.32	50.57
-Other financial liabilities	-	-
(ii) Provisions	15.20	13.18
(iii) Deferred tax Liabilities	318.38	270.18
Total Non-Current Liabilities	382.90	333.93
Current liabilities		
(i) Financial liabilities		
-Lease Liabilities	3.00	3.23
-Trade payables		
Micro Enterprises and Small Enterprises	-	-
Other than micro and small enterprises	763.52	745.46
-Other financial liabilities	5.74	17.59
(ii) Provisions	11.39	11.93
(iii) Other current liabilities	45.06	43.41
Total Current Liabilities	828.71	821.62
TOTAL EQUITY AND LIABILITIES	12,029.58	11,123.14



Supriya Lifescience Ltd

CIN No: L51900MH2008PLC180452

Cash flow statement for the period ended September 30, 2025

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	September 30, 2025	September 30, 2024
A CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	1,157.30	1,218.39
<u>Adjustments for</u>		
Depreciation and Amortization	130.90	94.00
Interest Income (Net of Expenses)	(42.02)	(18.85)
Dividend Received	-	(0.05)
Employee Benefit	(0.94)	7.01
Loss on Sale of fixed Assets	0.30	0.06
Operating profit before working capital changes	1,245.54	1,300.56
Adjustments for movement in working capital		
Adjustments for (increase)/ decrease in operating assets		
Trade Receivables	(207.54)	59.57
Inventories	(244.64)	(227.36)
Other Non Current & Current Assets	32.86	83.15
Other Non Current & Current Financial Assets	(23.17)	18.62
Loans and Advances	1.07	(0.83)
	(441.42)	(66.85)
Adjustments for increase/ (decrease) in operating liabilities		
Trade payables	18.06	28.37
Other Non Current & Current Financial Liabilities	(11.86)	14.01
Other Non Current & Current liabilities	(0.17)	(53.34)
	6.02	(10.96)
(Income tax paid)/net of refund	(254.50)	(301.13)
Net Cash generated from Operating Activities	555.65	921.62
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(422.49)	(758.25)
(Purchase)/ Sale of Investments	66.93	(86.92)
Interest Income	51.28	19.80
Dividend Received	-	0.05
Net Cash generated/(outflow) from Investing Activities	(304.29)	(825.32)
C CASH FLOW FROM FINANCING ACTIVITIES		
Finance Cost	(9.26)	(0.95)
Dividend Paid	-	-
Repayment of Lease liability	(1.49)	(1.78)
Net Cash generated from Financing Activities	(10.75)	(2.73)
Net Increase/(Decrease) in Cash and Cash equivalents	240.61	93.59
Cash and Cash Equivalents at the end of previous period	791.54	749.56
Cash and Cash Equivalents as at the end of the reporting period	1,032.15	843.14

